ArticleMMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports2024
U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.
Article in MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Misoprostol for intrauterine device placement.The Cochrane database of systematic reviews · 2025Pooled it
- Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.The Journal of clinical endocrinology and metabolism · 2025Guideline
- U.S. Selected Practice Recommendations for Contraceptive Use, 2024.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2024Guideline
- Breastfeeding after immediate vs delayed postpartum contraceptive implant placement: a noninferiority randomized controlled trial.American journal of obstetrics and gynecology · 2025Trial
- Contraceptive Efficacy and Comparative Side Effects of a Mini Copper Intrauterine Device.NEJM evidence · 2025Trial
- A cohort study on inflammatory response and coagulation function changes in women with silver clip or silk ligation sterilisation.Annals of medicine · 2026Article
- Building a Framework for Sexual and Reproductive Health Care in the Rheumatology Context: Content and Approaches.Arthritis care & research · 2026Review
- Translation Validation, Software Adaptation, and Usability Testing of a Spanish Contraception Decision Tool: Protocol for a Mixed Methods Pilot Study.JMIR research protocols · 2026Article
- Combined hormonal versus nonhormonal versus progestin-only contraceptives for postpartum contraception in lactating individuals.The Cochrane database of systematic reviews · 2026Article
- Oral contraceptive-associated hypertension as an under-recognized contributor to secondary and apparent resistant hypertension: agent-specific blood pressure liability, RAAS testing pitfalls, and practical assessment.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Contraceptive management in people with epilepsy: A narrative review of drug interactions, special populations, and clinical guidance.Epileptic disorders : international epilepsy journal with videotape · 2026Review
- Postpartum Long-Acting Reversible Contraception Use Among People With Sickle Cell Disease in the United States.O&G open · 2026Article
- From Authorization to Access: A Synthesis of Implementation Barriers and Strategies for Pharmacist-Prescribed Contraception.Health care analysis : HCA : journal of health philosophy and policy · 2026Article
- From Authorization to Access: A Synthesis of Implementation Barriers and Strategies for Pharmacist-Prescribed Contraception.Health care analysis : HCA : journal of health philosophy and policy · 2026Article
- Development of a User-Informed Decision Aid for Contraceptive Decision-Making Among Adolescents and Young Adults: Qualitative Study.JMIR formative research · 2026Article
- Cultural Adaptation and Selection of a Minimal Set of Variables from Two Adolescent Pregnancy Risk Instruments (IRENE and REND) in Colombian Schoolgirls.Nursing reports (Pavia, Italy) · 2026Article
- GyneFix levonorgestrel-releasing intrauterine system for Chinese patients: a preliminary retrospective self-controlled observational study.BMC women's health · 2026Observational
- Prescribed Short-Acting Hormonal Contraceptive Use Among Premenopausal Females.JAMA network open · 2026Article
- Using updated clinical recommendations to support contraceptive decision-making: U.S. medical eligibility criteria for contraceptive use, 2024.Contraception · 2026Review
- Call to action: identifying an underlying bleeding disorder in adolescents with heavy menstrual bleeding.Research and practice in thrombosis and haemostasis · 2026Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2024 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by persons who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during January 25-27, 2023. The information in this report replaces the 2016 U.S. MEC (CDC. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR 2016:65[No. RR-3]:1-103). Notable updates include 1) the addition of recommendations for persons with chronic kidney disease; 2) revisions to the recommendations for persons with certain characteristics or medical conditions (i.e., breastfeeding, postpartum, postabortion, obesity, surgery, deep venous thrombosis or pulmonary embolism with or without anticoagulant therapy, thrombophilia, superficial venous thrombosis, valvular heart disease, peripartum cardiomyopathy, systemic lupus erythematosus, high risk for HIV infection, cirrhosis, liver tumor, sickle cell disease, solid organ transplantation, and drug interactions with antiretrovirals used for prevention or treatment of HIV infection); and 3) inclusion of new contraceptive methods, including new doses or formulations of combined oral contraceptives, contraceptive patches, vaginal rings, progestin-only pills, levonorgestrel intrauterine devices, and vaginal pH modulator. The recommendations in this report are intended to serve as a source of evidence-based clinical practice guidance for health care providers. The goals of these recommendations are to remove unnecessary medical barriers to accessing and using contraception and to support the provision of person-centered contraceptive counseling and services in a noncoercive manner. Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services. This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health care providers about contraceptive use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.